Navigation Links
Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
Date:1/14/2008

CARMIEL, Israel, Jan. 14 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that it has signed a lease agreement for the expansion of its manufacturing and research facility. The expanded space, located in the Company's facility in Carmiel, Israel, will provide the Company with approximately three times its current manufacturing space in anticipation of the potential commercialization of the Company's lead product candidate, prGCD, a therapeutic protein for the treatment of Gaucher disease.

The term of the lease agreement is 7.5 years with options to extend the life of the lease for up to 15 additional years. The Company intends to use the expanded facility for the manufacture of prGCD. The Company expects the facility to continue enjoying the Approved Enterprise status originally granted to the facility by the Investment Center of the Israeli Ministry of Industry, Trade and Labor. Under Israel's Law for the Encouragement of Capital Investments, 1959, the income from an Approved Enterprise will be exempt from taxation in Israel for a period of 10 years, commencing with the year in which taxable income is first generated from the Approved Enterprise.

Commenting on the expansion of the manufacturing facility, Yossi Maimon, the Company's Chief Financial Officer, said, "In light of the progress we have made to date in our prGCD program, we determined that we should commence the expansion of our current facility. Our expanded facility will provide us with the space and capacity required to bring prGCD to market and meet the anticipated demand for the drug following its anticipated approval by the United States Food and Drug Administration, while continuing to advance the research of the additiona
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
2. Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference
3. Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock
4. Protalix BioTherapeutics Announces Public Offering of Common Stock
5. Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference
6. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
7. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
8. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
9. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
10. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
11. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , , SINGAPORE, Dec. 2 /PRNewswire/...ns on its novel oral JAK2 inhibitor, SB1518, at Th...ng and Exposition in New Orleans. ,, Data will ...e 1 dose-escalation trial of SB1518 detailing its ...ynamic (PK/PD) profile in dose levels ranging from...
(Date:12/2/2009)... , , QUEBEC CITY, Dec. 2 /PRNewswire-Firs...X: AEZ) (the "Company"), a global biopharmaceutica...y, today announced that the U.S. Food and Drug Adm...on for the Company,s PI3K/Akt pathway inhibitor co...f relapsed/refractory multiple myeloma. Keryx Biop...
(Date:12/2/2009)... , , HOBOKEN, N.J., Dec. 2 /PRNewswire/ ...40 percent to 45 percent of Americans diagnosed wi...tinopathy. Diabetic retinopathy, damage to the re...se of blindness in people with diabetes and is one...ct, up to 80 percent of all patients who,ve had di...
(Date:12/1/2009)... , , NEW YORK, Dec. 1 /PRNewswire/ ...search report is available in its catalogue: ,,.../www.reportlinker.com/p0164494/Chromium---Global-M...mium is primarily influenced by stainless steel, w...e markets is also important for growth of chromium...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9
...r,s note: This is the fourth in a series of articl...ogy or biotechnology sectors. , , Madison, Wis....would be moving on to forming the entity. In the ...he last column that bears addressing. As a remind...cussed naming the entity. , ,These columns have b...
...e: read the first exclusive interview with David W... The new year will officially begin a new era of l...over for retiring chief executive James Barr on Ja...become president and CEO of TDS Telecommunications...ary, TDS Metrocom . , ,He will be taking over d...
...on, Wis. - Third Wave Technologies, Inc ., a man...bmitted an application to the U.S. Food and Drug A...is molecular test. , ,The test product, which Thi...rmine Cystic Fibrosis carrier status in adults, an...sting in newborns and children. Cystic Fibrosis is...
Other Biology Technology:Early Stage, Step 4: Cautionary trademark tales 2Early Stage, Step 4: Cautionary trademark tales 3
(Date:12/3/2009)...eads the world when it comes to investment in ener...g and Physical Sciences Research Council (EPSRC) C...eded: "Scientific and engineering research has alr... power solutions, but more investment is needed to...f we are to meet our carbon emission targets by 20...
(Date:12/2/2009)...ELPHIA New study results strengthen the evidence ...d of time have an increased risk for developing co...sk factors. , "This provides one more reason no...senior author Michael J. Thun, M.D., M.S., vice pr...search at the American Cancer Society. "Colorectal...
(Date:12/2/2009)...PHIA Assurance of a cancer-free status did not pr...zed tomography (CT) lung-cancer screening program ...te in a study published in Cancer Epidemiology, B... Association for Cancer Research. The December iss...findings should negate widespread concern in the l...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Cigarette smoking increases colorectal cancer risk 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Intimate abuse study finds clear links with poor health and calls for holistic primary care approach 50770 1Intimate abuse study finds clear links with poor health and calls for holistic primary care approach 50770 2Battle of the sexes benefits offspring says research 9115 1Battle of the sexes benefits offspring says research 9115 2Jackson 26amp 3B Coker to Spotlight Health Care Executive Insights 50767 1Jackson 26amp 3B Coker to Spotlight Health Care Executive Insights 50767 2Jackson 26amp 3B Coker to Spotlight Health Care Executive Insights 50767 3
...s to gaining fat, insects and mammals may have som...1, 2006, Cell Metabolism. The study finds that the...ient suite of genes involved in determining the fa...nt role in fat formation in both flies and mice. T...ct of genes on fat storage from insects to mammals...
...e you mutter about the high cost of relationship m...share your pain. In the first study to examine th...ciate professor of biology at McMaster University,... behavioural stress on microbes. His findings are ...shed by the Genetics Society of America. , "Ther...
...from Imperial College London shows that robot assi...han conventional surgery. , The team of surgeons t...improve surgical outcomes for patients undergoing ... the surgeon to line up the replacement knee parts...t 27 patients undergoing unicompartmental knee rep...
Other Biology News:Insects and mammals share common fat-building pathway, study suggests 2Sex: It's costly but worth it. Just ask a microbe 2Robot assisted surgery more accurate than conventional surgery 2
PROTEAN II XL Cell, wide format from Bio-Rad
PROTEAN II xi Cell, 20 cm, without spacers and combs from Bio-Rad
StemSep Rhesus CD4+ T Cells, 2 mL Kit from StemCell Technologies, Inc.
...100 high pressure dual piston pump and the Adept C...ility. The system is provided with PowerStream da...., The CE 4901 PowerStream software operating in ...00, offers the same data processing power as the C...
Biology Products: